dupilumab
sanofi,regeneron
['dupixent', '$sny', '$regn']
dupixent late-breaking phase 3 data at the eadv 2022 congress showed significant improvements in signs and symptoms of prurigo nodular.. $regn $sny 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice